What are the novel therapies in the treatment of constipation?

Updated: Mar 30, 2020
  • Author: Marc D Basson, MD, PhD, MBA, FACS; Chief Editor: BS Anand, MD  more...
  • Print

The FDA approved prucalopride, a serotonin-4 receptor agonist indicated for chronic idiopathic constipation (CIC), in December 2018. [28] Approval was based on an integrated analysis of six double-blind, placebo-controlled, randomized, multicenter clinical studies lasting 12 weeks (studies 1-5) or 24 weeks (study 6). An integrated analysis of six main clinical trials (N=2484) found that significantly more patients treated with prucalopride achieved an average of three or more spontaneous, complete bowel movements per week over the 12-week treatment period compared with placebo (27.8% vs 13.2%; P< .001). A rapid response was seen with prucalopride as early as week 1, with improvements maintained throughout 12 weeks of treatment. [29, 30]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!